Publication: 3647

Publication: 3647

Long term results of Alliance A041202 show continued advantage of ibrutinib-based regimens compared with bendamustine plus rituximab chemoimmunotherapy

DOI

URL

Google Scholar

Citation:: Blood vol 138 (Supplement 1) 639

Meeting Instance:: ASH 2021
Year:: 2021
Type:: Abstract
Sub type:: Oral
Funding:: NCTN
Endpoint:: Primary
Analysis:: Long-Term-Followup
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: epub

Note:

Methodological:: No
Biospecimen:: Yes
SDC:: No

Parents:: None
Children:: 3856 4061

Program:: OGC
Primary Committee:: Leukemia
Sec. Committees:

Pharmas:
Grants:: U10CA180821, U10CA180882, U24CA196171, K23CA178183, R01CA183444, U10CA180863 (CCTG), U10CA180820 (ECOG-ACRIN), U10CA180888 (SWOG);

Corr. Author:
Authors:: Jennifer A. Woyach Amy S. Ruppert Nyla Heerema Weiqiang Zhao Allison M Booth Wei Ding Nancy L. Bartlett Danielle M Brander Paul M Barr Kerry A Rogers Sameer Parikh Steven Coutre Arti Hurria Gerard Lozanski Sreenivasa Nattam Richard A. Larson Harry Erba Mark Litzow Carolyn Owen James Atkins Jeremy Abramson Jennifer Brown Rich Little Scott E. Smith Richard M. Stone Sumithra Mandrekar John C. Byrd

Networks:: IL017, LAPS-IL057, LAPS-MA036, LAPS-MN026, LAPS-MO011, LAPS-NC010, LAPS-OH007, NC002, NY167, OH070

Study: Alliance-A041202
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 3

Keywords: